Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

about

Interventional Left Atrial Appendage Closure Affects the Metabolism of Acylcarnitines.

P2860

Q50133651-C57CA683-EC7F-40C2-A5E4-591F5827802C

P2860

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

Item

http://www.wikidata.org/entity/Q41490689

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

@en

type

Item

label

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

@en

prefLabel

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

@en

P1476

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

@en

P2093

Annika Wenke

http://www.w3.org/2001/XMLSchema#string

Benjamin Sartorius

http://www.w3.org/2001/XMLSchema#string

Christian Fastner

http://www.w3.org/2001/XMLSchema#string

Jakob Triebel

http://www.w3.org/2001/XMLSchema#string

Thomas Bertsch

http://www.w3.org/2001/XMLSchema#string

Thomas Roth

http://www.w3.org/2001/XMLSchema#string

Ursula Hoffmann

http://www.w3.org/2001/XMLSchema#string

P2860

State of the Art: Newer biomarkers in heart failure

--LAA Occluder View for post-implantation Evaluation (LOVE)--standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics.

Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage With the Watchman Device.

Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug.

Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study.

Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.

P2888

s41598-017-08999-4

P304

9028

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-08999-4

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28831085

http://www.w3.org/2001/XMLSchema#string

P932

5567360

http://www.w3.org/2001/XMLSchema#string

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

about

P2860

P2860

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932